GLPwatch
Papers (10404)
Page 78 of 174, ranked by citation count.
- Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
- Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.
- Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
- SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
- Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.
- Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
- Obesity drugs aren't always forever. What happens when you quit?
- Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue.
- Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.
- Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence.
- Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
- Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
- Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.
- Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway.
- Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
- Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
- Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.
- Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries.
- GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report.
- Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.
- Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice.
- Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.
- Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats.
- Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity.
- Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
- Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
- Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.
- The effects of a GLP-1 analog liraglutide on reward value and the learned inhibition of appetitive behavior in male and female rats.
- Combination therapies for type 1 diabetes: why not now?
- Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.
- Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.
- Liraglutide Protects Neurite Outgrowth of Cortical Neurons Under Oxidative Stress though Activating the Wnt Pathway.
- Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
- Semaglutide for weight loss: unanswered questions.
- Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
- Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.
- Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials.
- Liraglutide abrogates nephrotoxic effects of chemotherapies.
- Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.
- Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
- Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
- The promise of tirzepatide: A narrative review of metabolic benefits.
- Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions.
- Design, evaluation, and in vitro-in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide.
- Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.
- Liraglutide for treating type 1 diabetes.
- New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
- Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.
- The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells.
- A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.
- Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-analysis.
- Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
- Tirzepatide adds hepatoprotection to its armoury.
- Semaglutide mitigates testicular damage in diabetes by inhibiting ferroptosis.
- GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
- Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma.
- Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats.
- Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States.
- Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months.